Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5173028 | 0.87 | SCN4A (0.41) | — | |
| SCHEMBL5174166 | 0.86 | — | — | |
| SCHEMBL7596570 | 0.86 | — | — | |
| SCHEMBL5175322 | 0.84 | — | — | |
| SCHEMBL5174765 | 0.84 | — | — | |
| SCHEMBL5200173 | 0.81 | CYP1A2 (0.33) | CYP1A2CYP2C19OPRM1 | |
| SCHEMBL5174496 | 0.80 | AKT1 (0.43) | CYP1A2CYP2C19 | |
| SCHEMBL5172997 | 0.80 | AKT1 (0.43) | CYP1A2CYP2C19 | |
| SCHEMBL5174551 | 0.78 | CYP1A2 (0.36) | CYP1A2CYP2C19 | |
| SCHEMBL5174053 | 0.78 | CYP1A2 (0.41) | CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257535-B1 | SUBSTITUTED PYRIDINE COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LAB (US) | 2007-05-23 | — | — | EP | disclosed |
| US-6656958-B2 | Preferred compounds are 3'-(5'- and/or 6'-substituted) pyridyl ethers; selectively controlling neurotransmitter release in mammals using these compounds | ABBOTT LABORATORIES | 2003-12-02 | — | — | US | disclosed |
| EP-1257535-A1 | SUBSTITUTED PYRIDINE COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020058646-A1 | Substituted pyridine compounds useful for controlling chemical synaptic transmission | ABBVIE INC. | 2002-05-16 | — | — | US | disclosed |
| US-20010034357-A1 | Substituted pyridine compounds useful for controlling chemical synaptic transmission | ABBOTT LABORATORIES | 2001-10-25 | — | — | US | disclosed |
| WO-2001056991-A1 | SUBSTITUTED PYRIDINE COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058646-A1 | Substituted pyridine compounds useful for controlling chemical synaptic transmission | SLC18A2, SLC18A3, CHRNA4 | OPRM1 304/4885CYP1A2 1893/4885CYP2C19 1658/4885 |
| US-20010034357-A1 | Substituted pyridine compounds useful for controlling chemical synaptic transmission | SLC18A2, SLC18A3, CHRNA4 | OPRM1 304/4885CYP1A2 1893/4885CYP2C19 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.